The web Browser you are currently using is unsupported, and some features of this site may not work as intended. Please update to a modern browser such as Chrome, Firefox or Edge to experience all features Michigan.gov has to offer.
Hepatitis B Information for Healthcare
-
Click here for VIS Page
-
Investigation and Reporting
Hepatitis B is a nationally notifiable disease. Health care providers should immediately report cases and possible cases to the local health department serving the residence of the case.
CDC VPD Surveillance Manual: Hepatitis B - Vaccine Preventable Diseases Surveillance Manual | CDC
For more information on Communicable Disease Reporting: Communicable Disease Reporting in Michigan
Notifiable diseases in Michigan:
Michigan's List of Notifiable Diseases 2025 By Condition
Michigan's List of Notifiable Diseases 2025 By Pathogen -
Clinical Features and Epidemiology
Hepatitis B chapter in the Pink Book on vaccine-preventable diseases
Chapter 10: Hepatitis B | Pink Book | CDC
Information on measles for health professionals, including epidemiology, communicability, and treatment
Clinical Overview of Hepatitis B | Hepatitis B | CDC
Disease presentation and common symptoms
Clinical Signs and Symptoms of Hepatitis B | Hepatitis B | CDC
-
ACIP Recommendations and MMWR Reports
ACIP Recommendations- Hep B
ACIP Recommendations: Hepatitis B Vaccine | ACIP Recommendations | CDC
ACIP Recommendations for Adults Aged 19-59 Years
Universal Hepatitis B Vaccination in Adults Aged 19–59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 | MMWR (cdc.gov)
ACIP Recommendations of Hep B Vaccine with a Novel Adjuvant
ACIP Recommendations- Prevention of Hep B Virus Infection
Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices | MMWR (cdc.gov) -
Healthcare Workforce
All healthcare personnel (HCP) who cannot document previous vaccination should receive either a 2-dose series of Heplisav-B at 0 and 1 month or a 3-dose series of either Engerix-B, PreHevbrio, Recombivax HB, or Twinrix at 0, 1, and 6 months.
HCP who perform tasks that may involve exposure to blood or body fluids should be tested for hepatitis B surface antibody (anti-HBs) 1–2 months after dose #2 of Heplisav-B or dose #3 of Engerix-B or Recombivax HB to document immunity.
-If anti-HBs is at least 10 mIU/mL (positive), the vaccinee is immune. No further serologic testing or vaccination is recommended.
-If anti-HBs is less than 10 mIU/mL (negative), the vaccinee is not protected from hepatitis B virus (HBV) infection, and should receive another 2-dose or 3-dose series of HepB vaccine on the routine schedule, followed by anti-HBs testing 1–2 months later. A vaccinee whose anti-HBs remains less than 10 mIU/mL after 2 complete series is considered a “non-responder."
For non-responders: HCP who are non-responders should be considered susceptible to HBV and should be counseled regarding precautions to prevent HBV infection and the need to obtain HBIG prophylaxis for any known or probable parenteral exposure to hepatitis B surface antigen (HBsAg)- positive blood or blood with unknown HBsAg status.
Non-responders should be tested for HBsAg and anti-HBc to determine infection status. Infected HCP should be counseled and medically evaluated. For HCP with documentation of a complete 2-dose (Heplisav-B) or 3-dose (Engerix-B, PreHevbrio, Recombivax HB, or Twinrix) vaccine series but no documentation of anti-HBs of at least 10 mIU/ mL (e.g., those vaccinated in childhood): HCP who are at risk for occupational blood or body fluid exposure might undergo anti-HBs testing upon hire or matriculation.
-
Educational Resources